Loading quotes...

Forecast

Buy
  1
Hold
  2
Sell
  0

Discussions in the community

  • Translated from German

    Roast my Portfolio – My Path to Financial Freedom 📈

    Nekromannte Nekromannte IV in Portfolio Roasts

    9 28
  • Translated from German

    Display of time even though it was not recorded

    p phil III in Schnack

    1 5
  • Translated from German

    Roast my portfolio 👀

    u user_e3b3a9 III in Portfolio Roasts

    11 15
  • Translated from German

    Would love your thoughts on this (;

    DividendCow DividendCow IV in Portfolio Roasts

    2 21
  • Translated from German

    How high is your annual dividend? If you like surveys as community comparisons, give it a like and I'll post them more often.

    Marcus Marcus I in Schnack

    37 14

  • Bayer rises sharply, but Monsanto legacy burdens hold back return to record high

    Bayer has more than doubled over the past twelve months and has nearly tripled since the start of 2025, but remains well below the 2015 record high of €145.80. The recovery is driven by approvals such as the stroke drug Asundexian, strong sales from products like Nubeqa, and upward revisions to annual targets after a net profit of €5.2 billion in nine months. At the same time, settlements in the Monsanto glyphosate litigation (Bayer has set aside $7.25 billion) and cost savings from 12,000 job cuts could reduce the risk. Sixteen of 21 analysts recommend the stock; the expected P/E ratio is 19, below the sector average of 23. » More on handelsblatt.com


  • Bayer raises annual targets after approval of stroke drug Asundexian

    Bayer saw its share price rise by more than 100 percent last year, but remains far below the all-time high before the Monsanto takeover. US approval for the stroke drug Asundexian and strong sales of new medicines such as Nubeqa and Kerendia are driving growth, prompting the group to raise its annual targets. Pressure from the wave of Monsanto lawsuits is easing after a ruling reduced many plaintiffs' chances of success and Bayer set aside $7.25 billion for out-of-court settlements. CEO Bill Anderson is focusing on cost cuts and simplified structures; analysts mostly rate the stock as buy and see the price-earnings ratio of around 19 as still attractive compared with the sector. » More on handelsblatt.com


  • Bayer receives approval for Asundexian in China and the US – Germany must wait

    Bayer has received approvals for the new stroke drug Asundexian in China and the US. Approval in Germany is still pending, so patients there will have to wait. The development reflects the growing practice of introducing new drugs first in foreign markets. » More on wiwo.de


  • Bayer: stroke drug Asundexian approved in USA and China, Europe still pending

    Bayer has received approvals for the Wuppertal-developed active ingredient Asundexian (brand name Sunharbo) in China and the USA; a European and German approval is being sought for next year. In a study, the drug reduced the risk of a recurrent ischemic stroke by 26 percent in over 12,000 patients. Analysts estimate peak annual sales potential of up to two billion euros in Europe and the USA; Bayer gives no official figures and initial sales expectations had been significantly higher. The group is simultaneously investing in a new plant in the USA while the market launch in Europe remains delayed. » More on wiwo.de


  • Bayer beats Q3 expectations thanks to pharma growth, analysts react differently

    Bayer reported a better-than-expected third quarter, driven by its pharmaceuticals division and products such as Nubeqa. Goldman and UBS raised their price target to €66.00 and recommend “Buy,” while Jefferies remains at “Hold” with a €46.00 target and points to possible one-off items. Adjusted EBITDA surprised on the upside, but core earnings per share stayed below consensus. Investors are cautious after the strong share-price rise, as parts of the success could be deemed unsustainable. » More on deraktionaer.de

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Bayer has already paid €0.11 in dividends. The last payout was in April.

Financials

In the last quarter, Bayer had revenue of €10.05B and net profit of -€672M
(EUR) September 2026
YoY
Revenue 10.05B 4.07%
Gross profit 5.45B 1.85%
Net profit -672M 30.22%
EBITDA 1.53B 151.65%

Fundamentals

Metric Value
Market capitalization
€56.14B
Number of shares
982.42M
52-week high/low
€57.84 - €26.64
Dividend yield
0.19%
Dividends TTM
€0.11
Beta
0.81
P/E ratio
-38.87
PEG ratio
0.01
P/B ratio
1.92
P/S ratio
1.23

Company profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Name
Bayer
CEO
Bill Anderson
Headquarters Leverkusen, nw
Germany
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
12/16/1996
Employees 87,775

Ticker symbols

Exchange Symbol
NASDAQ
BAYZF
XETRA
BAYN.DE
Stuttgart
BAYN.SG
München
BAYN.MU
Frankfurt
BAYN.F
Berlin
BAYN.BE
Düsseldorf
BAYN.DU
Hamburg
BAYN.HM
London
0P6S.L
SIX
BAYN.SW
Wien
BAYN.VI
Milan
1BAYN.MI
Warschau
BAY.WA
Wse
BAY.WA
🍪

Parqet  uses cookies. Learn more